
Vaccinatie tegen COVID-19: (logistieke) uitdagingen en oplossingen

Marc Kaptein, M.D.
Medisch Directeur
Pfizer Nederland



Uitdagingen 2020/2021

Januari; *nieuwe technologie, maar is die geschikt?*

Maart; *niet de eerste, of toch?*

Juli; *waar doen we onze Ph3 trial, ook in NL?*

September; *opstarten productie, maar hoe snel?*





October; *interim analyses, sinds wanneer zijn die politiek geladen?*

November; *distributie bij -70 graden Celsius, kan dat?*

Februari; *vaccin versus virus, wie wint?*

Januari

nieuwe technologie, maar is die geschikt?




Maart;

niet de eerste...of toch?



Juli

waar doen we onze Ph3 trial, ook in NL?




September

Opstarten productie, maar hoe snel?




Productie locaties EU








October

Interim analyses, sinds wanneer zijn die politiek geladen?



November

distributie bij -70° Celsius, kan dat?



*Distributie bij -70° Celsius,
het had gekund, ook in NL*



Februari

Vaccin versus virus, wie wint?

	200 + 100 mio doses		Additionele doses*	Voorlopig NL Allocation 3,89%
	Was (in doses /mio)	Nu (in doses / mio)	Optie op 200 mio doses (in doses/mio)	In doses / mio
Q4 2020	3,5	5,4	-	0,17
Q1 2021	53,1	56,1	-	2,36
Q2 2021	118,3	145,9	47,3	7,75
Q3 2021	99,9	81,6	93,3	6,90
Q4 2021	25	10,9	59,2	2,69
Total	300	300	200	19,5

*“Vaccins redden geen levens,
vaccinatie campagnes wel”*



Toekomst van vaccins en vaccin ontwikkeling?

“This rigorous demonstration of safety and efficacy less than 11 months later provides a practical demonstration that RNA-based vaccines, which require only viral genetic sequence information to initiate development, are a major new tool to combat pandemics and other infectious disease outbreaks. The continuous phase 1/2/3 trial design may provide a model to reduce the protracted development timelines that have delayed the availability of vaccines against other infectious diseases of medical importance”
NEJM, 10 Dec 2020

Toekomst mRNA vaccins?



- Cutting-edge design of lipid nanoparticle and modified mRNA
- Favorable safety and tolerability based on data to date
- Virus neutralizing antibodies and antigen specific CD4+ and CD8+ T cells
- Rapid and large-scale manufacturing



- Lyophilized formulation candidate for storage at refrigerator temperature
- Rapid adaptation to potentially emerging SARS-CoV-2 S protein sequence variants



- Opportunity to expand the platform to Flu with a self-amplifying multi-valent vaccine in 2022
- Improve current suboptimal Flu vaccine coverage
- Potentially address other viral diseases

Dank voor uw aandacht!

